R. R. Neubig

This study shows that inhibiting the Rho/MRTF pathway with CCG-257081 enhances the effectiveness of PD1/PDL1 blockade in BRAF-resistant melanoma.

This study identifies ATP12A as a potential therapeutic target for idiopathic pulmonary fibrosis by showing its overexpression in IPF lungs and its role in worsening fibrosis in mice.

This study shows that inhibiting the MRTF/SRF pathway with CCG-257081 prevents drug-induced lung fibrosis in mice, outperforming standard treatments in reducing fibrosis markers.

This study identifies that BRAF inhibitor-resistant melanoma cells are more sensitive to mitotic inhibitors, revealing a potential therapeutic strategy for resistant tumors.

This study identifies ibrutinib as a drug that reverses BRAFi resistance in melanoma by inhibiting YAP1 and acting through SRC kinase off-target effects, not BTK.

This study shows that inhibiting the Rho/MRTF pathway with CCG-222740 enhances trametinib's effectiveness in NRAS-mutant melanoma cell lines by reducing cell viability and clonogenicity.

This study identifies RhoA-mediated gene transcription as a mechanism of BRAF inhibitor resistance in melanoma, showing that targeting this pathway can re-sensitize resistant cells to vemurafenib.

This study identifies pirin as the molecular target of the CCG-1423/CCG-203971 compounds, showing its role in modulating MRTF-dependent gene expression and fibrosis.

This paper develops a mouse model with a human GNAO1 G203R mutation, showing sex-specific movement and seizure differences.